Ваши амбиции, наш опыт
НОВОСТИ
-
IBA sells RadioMed, part of IBA Dosimetry, to IZI...
IBA today announces that it has sold RadioMed Corporation (“RadioMed”), IBA’s VISICOIL™ fiducial markers business, to IZI Medical Products LLC, a leading interventional medical device company in a deal that is worth between USD 14 and 16 million to IBA. This concludes the strategic exercise with the decision to retain the remainder of the Dosimetry division within IBA Group. -
IBA ANNOUNCES A NEW UNIQUE FEATURE ON ITS CYCLONE®...
IBA announces a new unique feature on its Cyclone ® KIUBE cyclotron, THE CUSTOM ENERGY that will optimize the production of radioisotopes with high purity. -
IBA REPORTS HALF YEAR RESULTS FOR 2018
Louvain-La-Neuve, Belgium, August 23, 2018 - IBA ( Ion Beam Applications -
Запуск первого в России циклотрона нового поколения...
г. Лювен-ля-Нёв (Бельгия), 16.07.2018, IBA - Бельгийская компания IBA (Ion Beam Applications S.A., EURONEXT), лидер в области разработки решений для диагностики и лечения онкологических заболеваний, запустила первый в -
IBA REPORTS FULL YEAR RESULTS FOR 2017
Louvain-La-Neuve, Belgium, March 22, 2018 - IBA (Ion Beam Applications SA, EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces its audited consolidated annual results for the 2017 financial year.
